Healthcare -
Biotechnology - NASDAQ - US
$ 7.55
-9.8 %
$ 46.2 M
Market Cap
-0.43
P/E
1. INTRINSIC VALUE
Balance Sheet
Aligos Therapeutics, Inc.
| Current Assets | 62.1 M |
| Cash & Short-Term Investments | 56.9 M |
| Receivables | 0 |
| Other Current Assets | 5.2 M |
| Non-Current Assets | 7.95 M |
| Long-Term Investments | 0 |
| PP&E | 7.33 M |
| Other Non-Current Assets | 627 K |
| Current Liabilities | 21.7 M |
| Accounts Payable | 2.57 M |
| Short-Term Debt | 3.46 M |
| Other Current Liabilities | 15.7 M |
| Non-Current Liabilities | 77.3 M |
| Long-Term Debt | 4.92 M |
| Other Non-Current Liabilities | 72.4 M |
EFFICIENCY
Earnings Waterfall
Aligos Therapeutics, Inc.
| Revenue | 3.94 M |
| Cost Of Revenue | 0 |
| Gross Profit | 1.32 M |
| Operating Expenses | 93.1 M |
| Operating Income | -89.2 M |
| Other Expenses | 42.1 M |
| Net Income | -131 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aligos Therapeutics, Inc.
| Net Income | -131 M |
| Depreciation & Amortization | 2.62 M |
| Capital Expenditures | -130 K |
| Stock-Based Compensation | 8.45 M |
| Change in Working Capital | -4.96 M |
| Others | 39.3 M |
| Free Cash Flow | -80.9 M |
Wall Street Analysts Price Targets
Aligos Therapeutics, Inc.
ALGS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ALGS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aligos Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately.
globenewswire.com
- 1 week ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on June 10, 2025 (the “Grant Date”), in connection with the commencement of employment.
globenewswire.com
- 1 week ago
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET.
globenewswire.com
- 4 weeks ago
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.
globenewswire.com
- 1 month ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.
globenewswire.com
- 1 month ago
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.
globenewswire.com
- 1 month ago
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.
zacks.com
- 1 month ago
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025.
globenewswire.com
- 1 month ago
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.
globenewswire.com
- 1 month ago
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.
globenewswire.com
- 2 months ago
LIVMARLI Now Approved in Japan for ALGS and PFIC
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.
businesswire.com
- 3 months ago
Aligos Therapeutics Presents Positive Data at APASL 2025
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China.
globenewswire.com
- 3 months ago
8. Profile
Summary
Aligos Therapeutics, Inc. ALGS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 46.2 M
Dividend Yield
0.00%
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Contact
One Corporate Drive, South San Francisco, CA, 94080
https://www.aligos.com
IPO
Date
Oct. 16, 2020
Employees
70
Officers
Ms. Lesley Ann Calhoun CPA
Executive Vice President, Chief Financial Officer & Chief Operating Officer
Dr. Julian A. Symons DPHIL
Executive Vice President & Chief Scientific Officer
Dr. Tse-I Lin Ph.D.
Senior Vice President of Early Compound Development & Belgian Site Head
Dr. Sushmita M. Chanda DABT, Ph.D.
Executive Vice President & Chief Development Officer
Dr. Lawrence M. Blatt MBA, Ph.D.
Chief Executive Officer, President & Chairman of the Board
Ms. Kristina Engeseth M.B.A.
Senior Vice President and Head of People & Culture
Dr. David B. Smith Ph.D.
Executive Vice President & Head of Chemical Operations
Dr. Hardean E. Achneck M.D.
Executive Vice President & Chief Medical Officer